Key Points
- CEO Snehal Patel purchased 2,500 shares of Greenwich LifeSciences at an average $13.14 per share, investing $32,850 and increasing his direct stake to 5,606,602 shares. He also bought 1,100 additional shares the following day at $12.88 per share.
- GLSI opened at $13.45, near the lower end of its 12-month range of $7.78 to $34.10, with a market capitalization of approximately $197.5 million. Hedge funds and institutional investors own 4.16% of the company.
- Analyst views are mixed: HC Wainwright raised its price target to $69 and maintained a Buy rating, while other firms issued Sell ratings. The consensus rating is Hold, with a $57 average price target.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 1,100 shares of Greenwich LifeSciences stock in a transaction that occurred on Friday, July 24th. The shares were purchased at an average cost of $12.88 per share, for a total transaction of $14,168.00. Following the purchase, the chief executive officer directly owned 5,607,702 shares in the company, valued at $72,227,201.76. The trade was a 0.02% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Snehal Patel also recently made the following trade(s):
- On Thursday, July 23rd, Snehal Patel bought 2,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $13.14 per share, with a total value of $32,850.00.
Greenwich LifeSciences Stock Performance
GLSI opened at $13.45 on Wednesday. The firm's fifty day moving average is $21.63 and its two-hundred day moving average is $24.26. The firm has a market cap of $197.45 million, a PE ratio of -8.57 and a beta of 1.40. Greenwich LifeSciences, Inc. has a twelve month low of $7.78 and a twelve month high of $34.10.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on GLSI. Weiss Ratings restated a "sell (d-)" rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Wall Street Zen lowered Greenwich LifeSciences from a "hold" rating to a "sell" rating in a report on Saturday, June 6th. Finally, HC Wainwright boosted their target price on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a "buy" rating in a research note on Tuesday, July 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $57.00.
Check Out Our Latest Report on Greenwich LifeSciences
Hedge Funds Weigh In On Greenwich LifeSciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GLSI. Bank of America Corp DE increased its holdings in Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after purchasing an additional 1,322 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Greenwich LifeSciences by 109.6% in the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company's stock valued at $165,000 after purchasing an additional 4,102 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after purchasing an additional 3,168 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Greenwich LifeSciences during the fourth quarter worth about $203,000. Finally, Barclays PLC boosted its position in shares of Greenwich LifeSciences by 11.8% during the fourth quarter. Barclays PLC now owns 9,744 shares of the company's stock worth $205,000 after buying an additional 1,030 shares during the period. 4.16% of the stock is owned by institutional investors and hedge funds.
About Greenwich LifeSciences
(
Get Free Report)
Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company's product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.
Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
